EpimAb Biotherapeutics to Present Research at SITC Annual Meeting

October 11, 2024 by No Comments

SHANGHAI, Oct. 11, 2024 — EpimAb Biotherapeutics, a clinical stage biotechnology company focused on developing bispecific antibodies and T-cell engagers, will present two posters at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) in Houston, Texas, from November 6-10, 2024, at the George R. Brown Convention Center.

The posters will showcase: 1) preclinical findings for a novel cMet x EGFR bispecific antibody-drug conjugate (ADC) and 2) development and preclinical data for an innovative NK cell engager platform. Details for the presentations are as follows:

cMet x EGFR ADC

  • Title: A differentiated cMet x EGFR bispecific antibody-drug conjugate demonstrated broad antitumor activity and promising safety profile in preclinical models
  • Presentation number: 1048
  • Presentation Date: Saturday, November 9, 2024
  • Presentation Time: Poster Viewing 12:15-1:45pm CST; Poster Reception 7:10-8:30pm CST (Exhibit Halls AB)

NK Cell Engager Platform

  • Title: The development of IL15v-NKCE: A cutting-edge NK cell engager platform for cancer treatment
  • Presentation number: 1078
  • Presentation Date: Saturday, November 9, 2024
  • Presentation Time: Poster Viewing 12:15-1:45pm CST; Poster Reception 7:10-8:30pm CST (Exhibit Halls AB)

About EpimAb Biotherapeutics Inc

EpimAb Biotherapeutics Inc is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Leveraging its extensive internal research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is developing and globally advancing a unique pipeline of transformative preclinical and clinical assets aimed at benefiting cancer patients. For further information, please visit:

IR Contact
Dr. David Gu
+86-21-61951011

BD Contact
Dr. Jason Tang
+86-21-61951014